Regenxbio shares surge 7.99% on Stifel upgrade to Buy with $45 target

Shares of Regenxbio surged 7.99% in pre-market trading on Dec. 22, 2025, signaling renewed investor confidence in the gene therapy developer's growth trajectory.

The upward momentum followed a strategic upgrade from Stifel Nicolaus analyst Anabel Samimy, who reiterated a Buy rating while raising the price target to $45 from $40 per share. The adjustment reflects analysts' optimism about the company's pipeline advancements and commercialization potential, particularly as regulatory pathways for its lead programs show progress. With no conflicting market catalysts reported, the stock's pre-market performance underscores the sector's focus on long-term therapeutic innovation and capital efficiency.

Analysts have also highlighted the broader market context, noting that the biotech sector has been buoyed by favorable regulatory developments and increased venture capital funding. Regenxbio, as a leader in the AAV (adeno-associated virus) gene delivery platform, is positioned to benefit from this tailwind. Its recent collaboration with a European pharmaceutical giant to co-develop novel gene-based therapeutics has further elevated expectations for scalable production and global distribution capabilities.

With the stock's 52-week high now within reach, market participants are closely watching for confirmatory volume patterns that could indicate a breakout. Short-term traders are also assessing whether the recent rally is sustainable or if profit-taking may soon cap further gains. In the meantime, the company's R&D expenses have stabilized, and its balance sheet remains strong, allowing for continued investment in preclinical and Phase 1 studies.